Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 12/20 | 0.41 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18865679 | 0.95 | USP1 (0.44) | USP1PTGS2PTGS1MPOKCNH2 | |
| SCHEMBL18865985 | 0.95 | USP1 (0.44) | USP1PTGS2PTGS1MPOKCNH2 | |
| SCHEMBL31625222 | 0.89 | USP1 (0.39) | USP1PTGS2PTGS1MPOKCNH2 | |
| SCHEMBL31155892 | 0.87 | USP1 (0.41) | USP1MAP3K12PTGS2 | |
| SCHEMBL18865878 | 0.86 | USP1 (0.47) | USP1PTGS2PTGS1MPOKCNH2 | |
| SCHEMBL31625007 | 0.84 | USP1 (0.41) | USP1 | |
| SCHEMBL27174302 | 0.82 | USP1 (0.44) | USP1PTGS2PTGS1 | |
| SCHEMBL26627857 | 0.82 | USP1 (0.48) | USP1PTGS2PTGS1 | |
| SCHEMBL30966308 | 0.82 | USP1 (0.44) | USP1PTGS2PTGS1 | |
| SCHEMBL27097116 | 0.81 | USP1 (0.37) | USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129135-A2 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | MEDIVIR AB (SE) | 2024-02-22 | — | — | US | disclosed |
| EP-4308566-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | Tango Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| CN-117425656-A | Purine derivatives as anticancer agents | 探戈医药股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2023148643-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-08-10 | — | — | WO | disclosed |
| WO-2022197892-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | TANGO THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | RRM2, TYMP, PNP | USP1 1532/4885MAP3K12 2639/4885PTGS2 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.